Summary
Cannot evaluate alignment because FDA-approved prescribing information (label text/sections) was not provided in the prompt.
Category Scores
Accurate Statements
Unsupported Statements
Diarrhea is a known possible side effect of Keytruda (pembrolizumab).
No label text provided to verify that the FDA-approved Keytruda prescribing information lists diarrhea as an adverse reaction.
Diarrhea associated with Keytruda can occur as part of immune-related inflammation of the gut called colitis.
No label text provided to verify immune-mediated colitis/immune-related gastrointestinal inflammation as described.
Keytruda-related diarrhea can range from mild loose stools to more severe diarrhea that may require medical treatment.
No label text provided to verify the labeled severity spectrum and need for medical treatment.
Diarrhea can occur at any time during Keytruda treatment.
No label text provided to verify timing language for diarrhea during treatment.
Immune-related side effects of Keytruda often show up after starting therapy.
No label text provided to verify typical onset timing.
Immune-related side effects of Keytruda can also develop later.
No label text provided to verify later onset.
If diarrhea starts or worsens during Keytruda treatment, it should be treated as potentially immune-related until proven otherwise.
No label text provided to verify the labeled clinical approach (treat as immune-related until proven otherwise).
Symptoms that suggest Keytruda-related colitis include more frequent or watery stools.
No label text provided to verify symptom descriptors.
Symptoms that suggest Keytruda-related colitis include abdominal pain or cramping.
No label text provided to verify symptom descriptors.
Symptoms that suggest Keytruda-related colitis include blood or mucus in stool.
No label text provided to verify symptom descriptors.
Symptoms that suggest Keytruda-related colitis include fever or feeling very unwell.
No label text provided to verify symptom descriptors.
Immune-related colitis sometimes requires prescription treatment, often corticosteroids.
No label text provided to verify treatment requirements and corticosteroids as a common approach.
Clinicians consider severity, timing, and other symptoms to decide whether diarrhea is likely Keytruda-related colitis versus an infection.
No label text provided to verify the labeled decision factors vs infection.
Diarrhea/colitis can also occur with other immune checkpoint inhibitors because they can similarly trigger immune-related inflammation.
No label text provided (and no basis provided) to verify statements about other drugs beyond Keytruda.
The Keytruda label specifically documents diarrhea as a possible side effect, including immune-related gastrointestinal events.
No label text provided to confirm that the label specifically documents these items.
Contradictions
Important Omissions
FDA label citations/wording to support evaluation of adverse reactions (diarrhea/colitis), immune-related adverse events timing, diagnostic approach, and management (e.g., corticosteroids) for Keytruda.
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
Without the FDA label text, the accuracy and completeness of safety-related claims (diagnosis and management framing for immune-related colitis) cannot be verified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Cannot Evaluate
Primary Issue
FDA-approved prescribing information was not provided, so label-based verification of each claim is impossible.
Suggested Improvement
Paste the relevant FDA label sections/text (e.g., Warnings and Precautions, Adverse Reactions) for Keytruda related to diarrhea/colitis and immune-mediated GI adverse reactions, then resend the AI claims to re-evaluate against exact label wording.